A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Currently, RSV vaccines are recommended for pregnant women between 32 and 36 weeks of pregnancy to pass on protection to a ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

The votes in favor of Merck’s shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom ...

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.